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Background: Dialysis patients have impaired host defense mechanisms and
frequently require antibiotics for various infective complications. In this study,
we investigated whether dialysis patients have greater risk for Clostridium difﬁcile-
associated diarrhea (CDAD).
Methods: During the 4-year study period (2004–2008), 85 patients with CDAD
were identiﬁed based on a retrospective review of C difﬁcile toxin assay or
histology records. Nosocomial diarrheal patients without CDAD were considered
as controls (n¼403). We assessed the association between renal function and the
prevalence and clinical outcomes of CDAD.
Results: There was a signiﬁcant difference in the prevalence rate of chronic kidney
disease (CKD) between CDAD and non-CDAD patients (Po0.001). Sixteen patients
(18.8%) of the CDAD group were treated with dialysis, whereas 21 patients (5.2%)
of the non-CDAD group were treated with dialysis. There was a signiﬁcant
association between renal function and CDAD in patients on dialysis [odds ratio
(OR)¼4.44, 95% conﬁdence interval (CI) 2.19–8.99, Po0.001], but not in patients
with CKD stage 3–5 (OR¼1.10, 95% CI 0.63–1.92, P¼0.73). In multivariate analysis,
CKD stage 5D was an independent risk factor for the development of CDAD
(OR¼13.36, 95% CI 2.94–60.67, P¼0.001).
Conclusion: Our data indicate that dialysis patients might be at a greater risk of
developing CDAD, which suggests that particular attention should be provided to
CDAD when antibiotic treatment is administered to dialysis patients.
& 2013. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
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.Introduction
Clostridium difﬁcile is the well-known causative organism
of antibiotic-associated diarrhea, and is one of the most
common hospital-acquired infections. It accounts for 10–25%
of all cases of antibiotic-associated diarrhea and virtually all
cases of antibiotic-associated pseudomembranous colitis [1].
The major predisposing factor of C difﬁcile-associated diarrhea
(CDAD) is antimicrobial therapy, especially involving treatmentublished by Elsevier. This is an open access article under the CC BY-NC-
Table 1. Renal function of study groups
Renal function CDAD
(n¼85)
Non-CDAD
(n¼403)
P
eGFRZ60 mL/min/1.73 m2 65 (76.5%) 316 (78.4%) o0.001
eGFR 15–59 mL/min/1.73 m2 4 (4.7%) 66 (16.4%)
Dialysis treatment 16 (18.8%) 21 (5.2%)
CDAD, Clostridium difﬁcile-associated diarrhea; eGFR, estimated
glomerular ﬁltration rate.
Table 2. Baseline characteristics of study groups
CDAD Non-CDAD P
All patients
n 85 403
Kidney Res Clin Pract 32 (2013) 27–3128with broad-spectrum antibiotics such as penicillins, penicillin
plus beta-lactamase inhibitor combinations, cephalosporins, and
clindamycin [2]. However, other factors leading to the distur-
bance of the normal intestinal ﬂora may also contribute to the
development of CDAD. These include older age, severe under-
lying disease, gastrointestinal surgery, acid suppression, non-
steroidal anti-inﬂammatory drug use, and enteral feeding [3–4].
Patients on maintenance dialysis often need antibiotics for
treatment of a variety of infective complications. In addition, a
severely compromised host immune system may put dialysis
patients at particularly high risk for C difﬁcile infection.
Although there have been a few reports suggesting a relation-
ship between CDAD and chronic kidney disease (CKD) [5–8], it
is still unclear whether dialysis treatment is a risk factor for
CDAD. Here, we investigated whether dialysis patients are at
greater risk for CDAD.Age (y) 61.8712.7 62.0717.3 0.93
Male gender (n, %) 40 (47.1%) 196 (48.6%) 0.81
Serum creatinine (mg/dL) 1.6772.00 1.2371.42 0.02
eGFR (mL/min/1.73m2) 87.5750.4 84.87741.4 0.6
Serum albumin (g/dL) 3.170.7 3.370.7 0.03
Diabetes mellitus (n, %) 22 (25.9%) 102 (25.3%) 0.89
CKD stage 3–5
n 20 87
Age (y) 62.1711.3 69.4714.0 0.03
Male gender (n, %) 7 (35.0%) 44 (50.6%) 0.23
Serum creatinine (mg/dL) 4.7572.12 2.8272.49 0.002
eGFR (mL/min/1.73m2) 14.679.5 33.4717.9 o0.001
Serum albumin (g/dL) 2.770.7 3.070.7 0.17
Diabetes mellitus (n, %) 13 (65.0%) 39 (44.8%) 0.14
CKD stage 5D
n 16 21
Age (y) 60.4710.7 65.1712.6 0.24
Male gender (n, %) 6 (37.5%) 17 (81.0%) 0.02
Serum creatinine (mg/dL) 5.3771.83 6.1772.98 0.35
eGFR (mL/min/1.73m2) 10.973.9 9.874.0 0.41
Serum albumin (g/dL) 2.770.7 2.770.7 0.99
Diabetes mellitus (n, %) 11 (68.8%) 15 (71.4%) 1
CDAD, Clostridium difﬁcile-associated diarrhea; CKD, chronic kidney
disease; eGFR, estimated glomerular ﬁltration rate.Methods
This study was conducted at the Hallym University Kangnam
Sacred Heart Hospital in Korea from March 2004 to February
2008. During the 4-year period, 85 patients with CDAD were
identiﬁed on the basis of a retrospective review of C difﬁcile
toxin assay or histology records. Tests for C difﬁcile infection
were performed in patients with nosocomial diarrhea and fever.
The diagnosis of CDAD was established either by C difﬁcile toxin
A positivity in stool samples or by the presence of pseudomem-
branous colitis (identiﬁed by endoscopic examination). Stool
samples were examined for C difﬁcile toxin A using an enzyme-
linked ﬂuorescent assay (ELFA; VIDAS CD II, bioMe´rieux,
France). An aerobic bacterial culture (Salmonella and Shigella)
of stool specimens and an examination of ova and parasites
were also performed to exclude other forms of infectious
diarrhea. Hospitalized patients who showed diarrhea but were
negative for C difﬁcile toxin or showed negative endoscopy
ﬁndings were considered as controls (non-CDAD, n¼403).
We assessed renal function by measuring serum creatinine
levels before the onset of diarrhea. We also calculated the
estimated glomerular ﬁltration rate (eGFR) according to the
Modiﬁcation of Diet in Renal Disease (MDRD) study equation [9].
We deﬁned CKD as eGFRo60mL/minute/1.73 m2. Patients with
acute kidney injury (AKI) during the episodes of diarrhea were
excluded.
MDRD study equation: eGFR¼186 (serum creatinine)1.154
 (age)0.203 (0.742, if patient is female)
We assessed the association between renal function and
prevalence and clinical outcomes of CDAD. We also evaluated
comorbid conditions, recently prescribed antibiotics (within
8 weeks), laboratory parameters, treatment regimens, and the
relapse of CDAD.
According to the CDAD severity scoring system [10], patients
with Z 2 points were considered to have severe disease. One
point each was given for age 4 60 years, body temperature
438.3 1C, peripheral white blood cell (WBC) count 4 15,000
cells/mm3, and serum albumin levelo2.5 g/dL within 48 hours.
Two points were given for endoscopic evidence of pseudomem-
branous colitis or treatment in the intensive care unit. Relapse
was deﬁned as complete abatement of CDAD symptoms while
on initial antibiotic therapy with subsequent return of diarrhea
within 4 weeks after completion of treatment.
Results were presented as average7standard deviation.
Mann–Whitney U test was used to compare differences incontinuous variables such as age, serum creatinine, and albumin
levels. Differences in proportions were assessed using Fisher
exact test. Stepwise multivariate logistic regression analysis was
performed for a few variables investigated in univariate analysis.
A signiﬁcant level of 5% was considered statistically signiﬁcant.
Data were recorded using Microsoft Excel (Microsoft Corporation,
Redmond, WA, USA) and statistical analyses were performed
using the SAS package (version 6.10; SAS institute, Cary, NC, USA).Results
Data on renal function of CDAD (n¼85) and non-CDAD
patients (n¼403) at presentation are presented in Table 1.
There was a signiﬁcant difference in the prevalence of CKD
between CDAD and non-CDAD patients (Po0.001). In the
CDAD group, 16 patients (18.8%) were treated with dialysis
(12 hemodialysis, four peritoneal dialysis), and four patients
(4.7%) had CKD stage 3–4 (eGFR, 15–59 mL/minute/1.73 m2).
In the non-CDAD group, 21 patients (5.2%) had end-stage
renal disease (17 hemodialysis, four peritoneal dialysis), and
66 patients (16.4%) had CKD stage 3–4.
Table 2 shows the clinical characteristics of CDAD and non-
CDAD patients and the data stratiﬁed by CKD stage. Taking all
patients into account, the CDAD group had higher serum
Table 3. Risk factors associated with CDAD
Variables OR 95% CI P
Unadjusted
CKD stage 3–5 1.1 0.63–1.92 0.73
CKD stage 5D 4.44 2.19–8.99 o0.001
Age (y) 0.99 0.99–1.01 0.93
Diabetes mellitus 1.03 0.60–1.76 0.91
Male gender 0.91 0.59–1.50 0.79
Serum albumin (g/dL) 0.67 0.47–0.96 0.03
Serum creatinine (mg/dL) 1.19 1.02–1.31 0.02
eGFR (mL/min/1.73m2) 1 1.00–1.01 0.6
Adjusted
CKD stage 5D 13.36 2.94–60.67 0.001
Serum albumin (g/dL) 0.81 0.56–1.18 0.27
Serum creatinine (mg/dL) 0.77 0.58–1.02 0.07
CDAD, Clostridium difﬁcile-associated diarrhea; CI, conﬁdence interval;
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration
rate; OR, odds ratio.
Table 4. Comparisons of characteristics of CDAD patients by
dialysis treatment
Control
(n¼69)
Dialysis
(n¼16)
P
Age (y) 62.1713.2 60.4710.7 0.68
Male gender (n, %) 34 (49.3%) 6 (37.5%) 0.42
Serum creatinine (mg/dL) 0.8170.48 5.3771.83 o0.001
eGFR (mL/min/1.73m2) 104.4737.5 10.873.9 o0.001
Serum albumin (g/dL) 3.270.6 2.770.7 0.006
WBC count (/mm3) 983775615 14,59977547 0.03
Temperature (1C) 37.370.8 37.570.8 0.34
Duration of antibiotic use (d) 22.1715.7 24.8721.3 0.64
Diabetes mellitus (n, %) 11 (15.9%) 11 (68.8%) o0.001
Severe disease (n, %) 30 (43.5%) 9 (56.3%) 0.41
CDAD, Clostridium difﬁcile-associated diarrhea, eGFR, estimated
glomerular ﬁltration rate; WBC, white blood cell.
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than the non-CDAD group, but showed a signiﬁcantly lower
serum albumin level (3.170.7 vs. 3.370.7 g/dL, P¼0.03).
However, differences in serum albumin levels were not
signiﬁcant when CDAD and non-CDAD patients were com-
pared by CKD stage.
Univariate and multivariate analysis of risk factors for
CDAD are provided in Table 3. There was no signiﬁcant
association between renal function and development of CDAD
in patients with CKD stage 3–5 [odds ratio (OR)¼1.10, 95%
conﬁdence interval (CI)¼0.63–1.92, P¼0.73]. However, CKD
stage 5D showed a signiﬁcant association between renal
function and development of CDAD (OR¼4.44, 95%
CI¼2.19–8.99, Po0.001). Serum albumin (OR¼0.67, 95%
CI¼0.47–0.96, P¼0.03) and creatinine levels (OR¼1.19, 95%
CI¼1.02–1.31, P¼0.02) were signiﬁcantly associated with
CDAD. However, neither age nor diabetes mellitus or gender
was related to CDAD. In multivariate analysis, CKD stage 5D
was an independent risk factor for the development of CDAD
(OR¼13.36, 95% CI¼2.94–60.67, P¼0.001).
In the CDAD group, 81 patients (95.3%) had a record of
recent antibiotic therapy. Recently prescribed antibiotics for
any infectious cause were cephalosporins (n¼52), followed
by penicillin plus beta-lactamase inhibitor combinations
(n¼18), quinolone (n¼17), aminoglycoside (n¼10), glyco-
peptide (n¼9), antituberculosis medication (n¼2), macrolide
(n¼2), and clindamycin (n¼2). Thirty-six patients (42.4%)
had received two or more antibiotics. In dialysis patients,
cephalosporins and penicillin plus beta-lactamase inhibitor
combinations were the most commonly implicated agents.
There was no statistically signiﬁcant interaction between the
classes of antimicrobial agents and CDAD occurrence.
General characteristics of patients with CDAD stratiﬁed by
dialysis treatment are shown in Table 4. The signiﬁcantly
different characteristics between dialysis and nondialysis
group were the serum albumin level, peripheral WBC count,
and the presence of diabetes. We did not ﬁnd a difference in
the severity of CDAD in dialysis patients (56.3%) compared
with nondialysis patients (43.5%).
Initial antibiotic therapy for CDAD consisted of oral admin-
istration of metronidazole in all patients. The dose of oral
metronidazole was 250 mg four times daily, and the duration
of antibiotic treatment was 10–14 days. Treatment failure
occurred in three patients treated with metronidazole.Metronidazole failure occurred in two dialysis patients and
one nondialysis patient. However, these differences were not
statistically signiﬁcant. In three patients with refractory
symptoms, oral vancomycin (250 mg four times daily) was
administered. All patients showed complete resolution of
symptoms. During the study period, CDAD relapse occurred
in nine (10.6%) of the 85 patients treated with metronidazole.
Dialysis patients did not show signiﬁcantly higher relapse
rates than controls. Eleven patients (12.9%) died during the
study period. CDAD was considered to be the main cause
of death in one patient.Discussion
Our data showed that dialysis patients, but not patients with
CKD stage 3–5, had a higher incidence of CDAD. Despite a few
publications regarding patients with CKD or AKI, there have
been limited clinical studies reporting the development of CDAD
in dialysis patients. In a previous study conducted in a hospital
environment, the incidence of CDAD in the nephrology depart-
ment was signiﬁcantly higher than in the remaining depart-
ments of the hospital [6]; this study included mainly patients
with AKI. Jung et al [7] reported that it took a short period for
patients with impaired renal function to develop CDAD.
By contrast, Yousuf et al [8] reported that CKD (serum
creatinine level 4 1.5 mg/dL) was not a risk factor for CDAD,
but its presence was associated with increased recurrence of
CDAD. In this study, we also evaluated whether dialysis treat-
ment was a risk factor for CDAD.We found that CKD stage 5D but
not CKD stage 3–5, was a signiﬁcant independent risk factor for
the development of CDAD. This observation is consistent with the
results of the study by Eddi et al [5], who reported that the
association between CKD and CDAD remained insigniﬁcant in
patients with CKD who were not undergoing dialysis treatment.
However, the end-stage renal disease group did show a signiﬁ-
cant association. The reasons for this are not clear. Uremic
patients have impaired host defense mechanisms as compared
with nonuremic patients, which are typically ascribed to the
immunodeﬁcient state associated with uremia [11]. In addition,
exposure to the dialysis membrane or peritoneal dialysis solution,
the presence of vascular access, and episodes of latent or overt
peritonitis may chronically aggravate inﬂammatory processes in
patients undergoing maintenance dialysis. As a consequence,
they are more often treated with broad-spectrum antibiotics for
various infective complications.
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severe and recurrent disease [8,12–14]. Leung et al [15] also
reported that uremic patients suffered from severe disease with
explosive diarrhea and systemic toxicity. In this study, we did
not observe increased severity or relapse of CDAD in dialysis
patients. Although there was a signiﬁcant difference in serum
albumin levels between the dialysis and nondialysis groups, it
seemed to be associated with decreased renal function. Rubin
et al. [13] deﬁned severe disease as clinical decompensation
resulting in intensive care unit admission or death. CKD
occurred more commonly in cases of severe CDAD (33%) than
mild CDAD (10%). However, there is no consensus deﬁnition for
severe CDAD, nor is there agreement on the most important
clinical indicators that should be used to differentiate severity.
As a result, comparison between studies might be problematic.
This may account for our ﬁndings being different from those of
other studies. The majority of cases were promptly treated and
resolved without major sequelae. The development of relapse
(10.6%) was lower in our overall population than that reported
by others [16–18].
CDAD is mediated by two toxins: C difﬁcile toxin A and
toxin B. Diagnosis is generally based on the identiﬁcation of
toxin A or toxin B. The gold standard for diagnosis of CDAD is
tissue culture or cytotoxin assay of stool inﬁltrates. However,
these techniques are laborious. Instead, more rapid immu-
noassays [enzyme-linked immunosorbent assays (ELISAs)]
with comparable sensitivity (70–90%) and speciﬁcity (99%)
are now widely used [19]. In our study, stool specimens were
examined for toxin A using ELFA. The sensitivities of ELFA and
ELISA for toxin A are similar, but the speciﬁcity and positive
predictive value of ELFA are higher than those of ELISA [20].
Sigmoidoscopy or colonoscopy is not generally recommended
in patients with typical clinical ﬁndings and positive stool
toxin assay results. The importance of early diagnosis of CDAD
is emphasized because the incidence and severity appear to be
increasing [21,22]. When patients have classic clinical ﬁndings
but negative results in stool toxin assays, it is important to
consider CDAD and refer the patient for early endoscopy. In
our study, CDAD developed as early as 2 days after antibiotic
treatment completion; this was especially true in the case of
dialysis patients. Clinicians should have a high index of
suspicion of CDAD in dialysis patients developing diarrheal
disease, especially during or shortly after antimicrobial ther-
apy. Particular attention should be paid in dialysis patients.
Standard treatment for CDAD consists of oral administra-
tion of metronidazole or vancomycin. Metronidazole is less
expensive and has lower potential for the development of
resistant organisms. For these reasons, it has been commonly
recommended as ﬁrst-line therapy [23–25]. In this study,
metronidazole treatment failure occurred in two dialysis
patients and one control. However, there was no signiﬁcant
difference between the two groups, possibly because
of the small number of cases. The reasons for higher treat-
ment failure in dialysis patients are poorly understood.
We hypothesized that if the drug was being extensively
removed by hemodialysis or peritoneal dialysis, less metro-
nidazole was delivered to the mucosa and the colonic lumen
[26]. The limitations of our study were that it was retro-
spective and the sample size was relatively small.
In conclusion, our data indicate that dialysis patients might
be at greater risk for the development of CDAD. This suggests
that particular attention should be provided to CDAD, espe-
cially if the symptoms develop in dialysis patients.Conﬂict of Interest
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